Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study

Andreas G. Wibmer, Michael J. Morris, Mithat Gonen, Junting Zheng, Hedvig Hricak, Steven Larson, Howard I. Scher and Hebert Alberto Vargas
Journal of Nuclear Medicine August 2021, 62 (8) 1050-1056; DOI: https://doi.org/10.2967/jnumed.120.256602
Andreas G. Wibmer
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Morris
2Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mithat Gonen
3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junting Zheng
3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hedvig Hricak
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Larson
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Howard I. Scher
2Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hebert Alberto Vargas
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 62 no. 8 1050-1056
DOI 
https://doi.org/10.2967/jnumed.120.256602
PubMed 
33419944

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication September 10, 2020
  • Accepted for publication December 14, 2020
  • Published online July 30, 2021.

Article Versions

  • previous version (January 8, 2021 - 13:20).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Andreas G. Wibmer1,
  2. Michael J. Morris2,
  3. Mithat Gonen3,
  4. Junting Zheng3,
  5. Hedvig Hricak1,
  6. Steven Larson1,
  7. Howard I. Scher2 and
  8. Hebert Alberto Vargas1
  1. 1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;
  2. 2Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and
  3. 3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
  1. For correspondence or reprints, contact Andreas G. Wibmer (wibmera{at}mskcc.org).
View Full Text

Statistics from Altmetric.com

Cited By...

  • 6 Citations
  • 10 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients
    Matteo Bauckneht, Francesco Bertagna, Maria Isabella Donegani, Rexhep Durmo, Alberto Miceli, Vincenzo De Biasi, Riccardo Laudicella, Giuseppe Fornarini, Alfredo Berruti, Sergio Baldari, Annibale Versari, Raffaele Giubbini, Gianmario Sambuceti, Silvia Morbelli, Domenico Albano
    Prostate Cancer and Prostatic Diseases 2021 24 4
  • Salvage therapy for prostate cancer after radical prostatectomy
    Nicholas G. Zaorsky, Jeremie Calais, Stefano Fanti, Derya Tilki, Tanya Dorff, Daniel E. Spratt, Amar U. Kishan
    Nature Reviews Urology 2021 18 11
  • Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT
    Fadi Khreish, Kalle Ribbat, Mark Bartholomä, Stephan Maus, Tobias Stemler, Ina Hierlmeier, Johannes Linxweiler, Mathias Schreckenberger, Samer Ezziddin, Florian Rosar
    Cancers 2021 13 16
  • Freely Available, Fully Automated AI-Based Analysis of Primary Tumour and Metastases of Prostate Cancer in Whole-Body [18F]-PSMA-1007 PET-CT
    Elin Trägårdh, Olof Enqvist, Johannes Ulén, Jonas Jögi, Ulrika Bitzén, Fredrik Hedeer, Kristian Valind, Sabine Garpered, Erland Hvittfeldt, Pablo Borrelli, Lars Edenbrandt
    Diagnostics 2022 12 9
  • Starving lethal prostate cancer by targeting heat shock proteins and glycolytic enzymes
    Stephen R. Plymate, Cynthia Sprenger, Michael C. Haffner
    Cell Reports Medicine 2022 3 2
  • Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer
    Jiaxian Chen, Lin Qi, Yongxiang Tang, Guyu Tang, Yu Gan, Yi Cai
    Frontiers in Cell and Developmental Biology 2022 10
  • Nuclear Oncology
    Steven M. Larson
    2022
  • Nuclear Oncology
    Steven M. Larson
    2022
  • Nuclear Oncology
    Steven M. Larson
    2022
  • The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer
    Goutam Chakraborty, Subhiksha Nandakumar, Rahim Hirani, Bastien Nguyen, Konrad H. Stopsack, Christoph Kreitzer, Sai Harisha Rajanala, Romina Ghale, Ying Z. Mazzu, Naga Vara Kishore Pillarsetty, Gwo-Shu Mary Lee, Howard I. Scher, Michael J. Morris, Tiffany Traina, Pedram Razavi, Wassim Abida, Jeremy C. Durack, Stephen B. Solomon, Matthew G. Vander Heiden, Lorelei A. Mucci, Andreas G. Wibmer, Nikolaus Schultz, Philip W. Kantoff
    Clinical Cancer Research 2022 28 16

Article usage

Article usage: January 2021 to December 2022

AbstractFullPdf
Jan 20211741053
Feb 2021340017
Mar 2021218017
Apr 202112703
May 202116906
Jun 202113205
Jul 20213742357
Aug 2021116365109
Sep 20216071442
Oct 20215221928
Nov 2021344944
Dec 2021348722
Jan 20224751619
Feb 20226333622
Mar 20225130850
Apr 20224119626
May 20222420134
Jun 20223630323
Jul 20221535817
Aug 20221829332
Sep 20222233124
Oct 20221418828
Nov 2022158019
Dec 20222239117
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (8)
Journal of Nuclear Medicine
Vol. 62, Issue 8
August 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study
Andreas G. Wibmer, Michael J. Morris, Mithat Gonen, Junting Zheng, Hedvig Hricak, Steven Larson, Howard I. Scher, Hebert Alberto Vargas
Journal of Nuclear Medicine Aug 2021, 62 (8) 1050-1056; DOI: 10.2967/jnumed.120.256602

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study
Andreas G. Wibmer, Michael J. Morris, Mithat Gonen, Junting Zheng, Hedvig Hricak, Steven Larson, Howard I. Scher, Hebert Alberto Vargas
Journal of Nuclear Medicine Aug 2021, 62 (8) 1050-1056; DOI: 10.2967/jnumed.120.256602
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Fetal Dose from PET and CT in Pregnant Patients
  • Longitudinal Tau PET Using 18F-Flortaucipir: The Effect of Relative Cerebral Blood Flow on Quantitative and Semiquantitative Parameters
  • Differential Effects of Tau Stage, Lewy Body Pathology, and Substantia Nigra Degeneration on 18F-FDG PET Patterns in Clinical Alzheimer Disease
Show more Clinical Investigation

Similar Articles

Keywords

  • metastatic prostate cancer
  • 18F-FDG PET/CT
  • whole-body tumor burden
  • Overall survival
  • abiraterone
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire